MiNA Therapeutics
UK-based MiNA specializes in RNA activation therapeutics.
The company is developing a new class of medicines called small activating RNAs, which share many features with other RNA therapies but work through the distinct mechanism of RNA activation.
MiNA is partnering with pharma companies including AstraZeneca, Sosei Heptares and Servier, along with academic and research institutions.
Latest MiNA Therapeutics News & Features
5 April 2024
21 January 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze